eMedicine Specialties > Sports Medicine > Hip

Hip Tendonitis and Bursitis: Treatment & Medication

Author: Jeffrey Rosenberg, MD, Director of Primary Care Sports Medicine Fellowship, Assistant Residency Director, Mountainside Hospital and Mountainside Family Practice Associates; Consulting Staff, New Jersey Sports Medicine Institute
Coauthor(s): Rutvik Patel, DO, Fellow in Sports Medicine, Mountainside Sports Medicine
Contributor Information and Disclosures

Updated: Mar 31, 2008

Treatment

Acute Phase

Rehabilitation Program

Physical Therapy

The initial treatment for all chronic hip overuse injuries is similar, and this can be taught to patients in the office or via formal physical therapy. The initial alleviation of overuse pain is accomplished with relative rest of the painful area. The patient may continue to work out other body parts and attempt to maintain cardiovascular fitness. Pain relief can be improved with oral anti-inflammatory medications, as well as with modalities such as ice, ultrasound treatment, and high-intensity galvanic stimulation. Patients thought to have tendinopathy can use acetaminophen for pain relief because the affected tendon is not inflamed.
 
To prevent further symptoms, increasing the length of the muscle-tendon unit with stretching and increasing joint flexibility are paramount. Active stretching of the injured muscle must be accomplished to improve its length. At the same time, the injured muscle must be strengthened. Eccentric exercises, in which the muscle is lengthened and tightened at the same time (such as with lunges) should be added once full lengthening has returned. Once the proper length of the muscle has been attained and its strength restored, the addition of activity and sport-specific exercises completes the rehabilitation. Increasing the flexibility and strength of the opposing muscle groups is also required. 

Because most of these muscles attach to the pelvic ring, attention to stretching and strengthening of all peripelvic tissues is helpful. Increasing the strength of the abductor muscles, such as the gluteus medius, should improve pelvic stability. Manual therapies are also helpful for manipulating the symphysis pubis and SI joints.

Leg-length discrepancies greater than 1 cm should be corrected with shoe lifts to improve balance and pelvic symmetry. Likewise, correction of any pes planus and the use of anti-pronation devices with an over-the-counter or custom orthosis is imperative for active individuals who do weight-bearing exercises or who run and walk regularly.

Related eMedicine topics:
Lower Limb Orthotics
Pes Planus

Related Medscape topic:
Resource Center Exercise and Sports Medicine

Medical Issues/Complications

If the patient's condition is not responding as expected to treatment for the initial diagnosis, a second look at the symptoms and perhaps an additional piece of imaging may be performed to confirm that the diagnosis was appropriate (see Differentials and Other Problems to Be Considered).

Intra-abdominal or pelvic pathology can occasionally cause hip pain. If any gastrointestinal symptoms such as a change in bowel habits; the presence of blood in stool; or the presence of gynecologic symptoms such as bloating, new menstrual irregularities, or dyspareunia are present, a gastrointestinal or genitourinary workup may be necessary.

Related Medscape topics:
Resource Centers Gastroenterology
Resource Centers Ob/Gyn & Women's Health
Resource Centers Urology

Surgical Intervention

  • Surgical therapy for chronic hip overuse injuries is occasionally necessary. Partial tendon excision and debridement of tendon scars have been performed for both adductor and hamstring injuries that fail to resolve. These surgeries are usually reserved for high-level athletes whose conditions fail to improve and who return to activity with prolonged courses of physical therapy. After surgery, such a prolonged physical therapy is needed to return athletes to their full ROM and strength. 
  • Large avulsion fractures of the rectus, hamstring, and iliopsoas should be internally fixated. Likewise, large apophyseal avulsions (greater than 2 cm) should be repaired. Intra-articular disorders, such as labral tears, and intra-articular loose bodies need hip arthroscopy to improve an individual's symptoms and level of activity.

Recovery Phase

Rehabilitation Program

Physical Therapy

See Treatment, Acute Phase.

Tendinopathy treatment can often be frustrating for clinicians and patients alike. The degenerative tendon must be lengthened with aggressive and constant stretching. Eccentric exercises have been proven to decrease pain and return patients to a full level of activity in both hamstring and patellar tendinopathy.

Consultations

The treatment of hip overuse syndrome (traction tendinitis) is never a short-term proposition; thus, treating this condition effectively requires a team approach. Optimally, medical resources are available to include a physical therapist and a fitness trainer who are skilled in laddered, progressive exercise following an individual's injury.

Chronic hip pain often goes undiagnosed, leading to psychologic difficulties from the debilitating nature of the pain itself and the frustration of being unable to return to a sport or exercise in a timely fashion. A psychology consultation may be indicated in such cases.

Related Medscape topics:
Resource Center Depression
Resource Center Pain Management: Advanced Approaches to Chronic Pain Management
Resource Center Patient-Provider Relations in Psychiatry & Mental Health
CME Advances in Neuropathic Pain: Case Studies in Uncomplicated Postherpetic Neuralgia and Painful Diabetic Polyneuropathy
CME Most Patients Prefer Their Physicians to Greet Them With a Handshake and Introduction

Other Treatment (Injection, manipulation, etc.)

  • The treatment of greater trochanteric bursitis involves lengthening the tensor fasciae latae/iliotibial band complex. Additionally, an injection of corticosteroid into the affected bursa can be added if necessary. Likewise, injections into the iliopsoas bursa can be performed by experienced clinicians using ultrasound guidance.  
  • Interventional treatments for chronic tendinopathy have met with varied success. The goal of all of these therapies is to restart the healing process by increasing inflammation and blood flow into an area, thereby allowing new progenitor cells to come into the area, lay down healthier collagen, and improve the organization of collagen. Any patients who undergo these treatments should not use anti-inflammatory medications because these drugs will prevent the inflammation that is being sought. 
  • Prolotherapy (also called proliferative therapy) involves injecting 3% NaCl or 10% dextrose into and around the affected tendon to restart the inflammatory cascade. 
  • Injections of autologous whole blood and platelet-rich plasma concentrations have also been attempted for the treatment of tendinopathy in other parts of the body. Using these injections under ultrasound guidance will likely increase their effectiveness. Likewise, performing percutaneous needling of the tendon by fenestration with an 18- or 21-gauge needle before administration of the injection will improve the flow of blood and inflammation into the tendon.

Medication

For patients with hip overuse syndrome, medications are used primarily to decrease pain and inflammation. These agents are best used for short time periods in the acute setting after an injury to prevent further swelling and pain. 

Inflammation is part of the normal healing response and may be necessary to allow for complete tissue recovery. Some theories regarding tendinopathy involve the belief that stopping the healing response by halting all inflammation prevents the eventual recovery of tendons by interfering with normal collagen deposition and alignment. By preventing new blood-vessel formation into an injured area, complete healing does not occur.

In patients without known contraindications, nonsteriodal anti-inflammatory medications (NSAIDS) are preferred for short time periods for pain and inflammation control. Providers can decide which NSAIDS are the ones they are most comfortable using.

Nonsteroidal anti-inflammatory drugs (NSAIDs)

NSAIDs have analgesic, anti-inflammatory, and antipyretic activities. The mechanism of action of these agents is not known, but they may inhibit cyclooxygenase activity and prostaglandin synthesis. Other mechanisms may exist as well; these may include inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell-membrane functions.

Related eMedicine topic:
Toxicity, Nonsteroidal Anti-inflammatory Agents


Ibuprofen (Motrin, Excedrin IB, Ibuprin, Advil)

DOC for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.

Adult

200-400 mg PO q4-6h while symptoms persist; not to exceed 3.2 g/d

Pediatric

<6 months: Not established
6 months to 12 years: 4-10 mg/kg/dose PO tid/qid
>12 years: Administer as in adults

Coadministration with aspirin increases the risk of inducing serious NSAID-related adverse effects; probenecid may increase the concentrations and, possibly, the toxicity of NSAIDs; may decrease the effect of hydralazine, captopril, and beta-blockers; may decrease the diuretic effects of furosemide and thiazides; may increase PT duration when anticoagulants are taken (instruct patients to watch for signs of bleeding); may increase the risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Documented hypersensitivity; patients with peptic ulcer disease, recent GI bleeding or perforation, renal insufficiency, or a high risk of bleeding

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in patietns with congestive heart failure, hypertension, and decreased renal and hepatic function; caution in the presence of coagulation abnormalities or during anticoagulant therapy


Naproxen (Naprosyn, Anaprox, Aleve, Naprelan)

For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing the activity of cyclooxygenase, which results in a decrease of prostaglandin synthesis.

Adult

500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d

Pediatric

<2 years: Not established
>2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d

Coadministration with aspirin increases the risk of inducing serious NSAID-related adverse effects; probenecid may increase the concentrations and, possibly, the toxicity of NSAIDs; may decrease the effect of hydralazine, captopril, and beta-blockers; may decrease the diuretic effects of furosemide and thiazides; may increase PT duration when anticoagulants are taken (instruct patients to watch for signs of bleeding); may increase the risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug.


Ketoprofen (Actron, Orudis, Oruvail)

For relief of mild to moderate pain and inflammation.
Small dosages initially indicated in small and elderly patients and in those with renal or liver disease. Doses over 75 mg do not increase the therapeutic effects. Administer high doses with caution and closely observe patient for response.

Adult

25-50 mg PO q6-8h prn; not to exceed 300 mg/d

Pediatric

<12 years: Not established
3 months to 12 years: 0.1-1 mg/kg PO q6-8h
>12 years: Administer as in adults

Coadministration with aspirin increases the risk of inducing serious NSAID-related adverse effects; probenecid may increase the concentrations and, possibly, the toxicity of NSAIDs; may decrease the effect of hydralazine, captopril, and beta-blockers; may decrease the diuretic effects of furosemide and thiazides; may increase PT duration when anticoagulants are taken (instruct patients to watch for signs of bleeding); may increase the risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in patients with congestive heart failure, hypertension, and decreased renal and hepatic function; caution in the presence of coagulation abnormalities or during anticoagulant therapy


Nabumetone (Relafen)

Nonacidic NSAID that is rapidly metabolized after absorption to a major active metabolite that inhibits cyclooxygenase enzyme, which in turn inhibits inflammation.

Adult

1-2 g PO qd

Pediatric

Not established

Coadministration with aspirin increases the risk of inducing serious NSAID-related side effects; probenecid may increase the concentrations and, possibly, the toxicity of NSAIDs; may decrease the effect of hydralazine, captopril, and beta-blockers; may decrease the diuretic effects of furosemide and thiazides; may increase PT duration when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase the risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently

Documented hypersensitivity; patients with active peptic ulceration, hepatic impairment

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Elderly patients may require lower doses; caution in the presence of hepatic and renal impairment

Cyclooxygenase-2 (COX-2) Inhibitors

COX-2 inhibitors are a class of NSAIDs that have a decreased incidence of adverse GI effects, such as gastritis and ulcers. COX-2 inhibitors may be indicated in patients with a history of gastric ulcers, who require anti-inflammatory medications.


Celecoxib (Celebrex)

Inhibits primarily COX-2, an isoenzyme that is induced during pain and with inflammatory stimuli. Inhibition of COX-1 may contribute to NSAID GI toxicity. At therapeutic concentrations, the COX-1 isoenzyme not inhibited; therefore, GI toxicity may be decreased. Seek the lowest dose for each patient.

Adult

200 mg/d PO qd; alternatively, 100 mg PO bid

Pediatric

Not established

Coadministration with fluconazole may increase celecoxib plasma concentrations because of inhibition of the celecoxib metabolism; coadministration with rifampin may decrease celecoxib plasma concentrations

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

May cause fluid retention and peripheral edema; caution in patients with compromised cardiac function, hypertension, conditions predisposing to fluid retention; caution in the presence of severe heart failure and hyponatremia because circulatory hemodynamics may deteriorate; NSAIDs may mask the usual signs of infection; caution in the presence of existing controlled infections; evaluate therapy when symptoms or laboratory results suggest liver dysfunction

Analgesics

Simple analgesics like acetaminophen may be preferred for conditions in which NSAID use is not advised or in which there is little suspicion of an underlying inflammatory process.

Tramadol hydrochloride is an opioid analgesic that has noradrenergic and serotonergic properties that may contribute to its analgesic activity. Tramadol is used for moderate to severe pain or in cases wherein NSAIDs cannot be taken. The potency of this agent is less than that of traditional opioids, and there is less (but not zero) addiction potential.


Acetaminophen (Aspirin-free Anacin, Tylenol, Feverall, Tempra)

DOC for pain in patients with documented hypersensitivity to aspirin or NSAIDs, those with upper GI disease, or those taking oral anticoagulants.

Adult

325-650 mg PO q4-6h or 1000 mg tid/qid; not to exceed 4 g/d

Pediatric

<12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d
>12 years: 325-650 mg PO q4h; not to exceed 5 doses in 24 h

Rifampin can reduce the analgesic effects of acetaminophen; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity.

Documented hypersensitivity; known G6PD deficiency

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Hepatotoxicity is possible in patients with chronic alcoholism following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; many OTC products contain acetaminophen, and combined use with these products may result in cumulative doses of acetaminophen that exceed the recommended maximum dose.


Tramadol (Ultram, Ultram ER)

Inhibits ascending pain pathways, altering perception of and response to pain. Also inhibits reuptake of norepinephrine and serotonin.

Adult

50-100 mg PO q4-6h; not to exceed 400 mg/d

Pediatric

Not established

Decreases carbamazepine effects significantly; cimetidine increases toxicity, risk of serotonin syndrome with coadministration of antidepressants

Documented hypersensitivity; opioid-dependent patients; concurrent use of MAOI or within 14 days; use of SSRIs, TCAs, opioids, acute alcohol intoxication

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Can cause dizziness, nausea, constipation, sweating, pruritus; additive sedation with alcohol and TCAs; abrupt discontinuation can precipitate opioid withdrawal symptoms; adjust dose in patients with liver disease, myxedema, hypothyroidism, hypoadrenalism; pregnancy, breast-feeding women; seizure; development of tolerance or dependency with extended use; swallow extended-release product whole: do not chew, crush, or split

More on Hip Tendonitis and Bursitis

Overview: Hip Tendonitis and Bursitis
Differential Diagnoses & Workup: Hip Tendonitis and Bursitis
Treatment & Medication: Hip Tendonitis and Bursitis
Follow-up: Hip Tendonitis and Bursitis
References

References

  1. Segal NA, Felson DT, Torner JC, et al. Greater trochanteric pain syndrome: epidemiology and associated factors. Arch Phys Med Rehabil. Aug 2007;88(8):988-92. [Medline].

  2. Browning KH. Hip and pelvis injuries in runners. Phys Sportsmed. 2001;29(1):23-34. [Full Text].

  3. DeAngelis NA, Busconi BD. Assessment and differential diagnosis of the painful hip. Clin Orthop Relat Res. Jan 2003;406:11-8. [Medline].

  4. Anderson K, Strickland SM, Warren R. Hip and groin injuries in athletes. Am J Sports Med. Jul-Aug 2001;29(4):521-33. [Medline].

  5. Adkins SB 3rd, Figler RA. Hip pain in athletes. Am Fam Physician. Apr 1 2000;61(7):2109-18. [Medline][Full Text].

  6. Johnston CA, Wiley JP, Lindsay DM, Wiseman DA. Iliopsoas bursitis and tendinitis. A review. Sports Med. Apr 1998;25(4):271-83. [Medline].

  7. Garrick JG, Webb DR. Sports Injuries: Diagnosis and Management. 2nd ed. Philadelphia, Pa: WB Saunders; 1999.

  8. Shbeeb MI, Matteson EL. Trochanteric bursitis (greater trochanter pain syndrome). Mayo Clin Proc. Jun 1996;71(6):565-9. [Medline].

  9. Kujala UM, Orava S, Karpakka J, Leppävuori J, Mattila K. Ischial tuberosity apophysitis and avulsion among athletes. Int J Sports Med. Feb 1997;18(2):149-55. [Medline].

  10. Margo K, Drezner J, Motzkin D. Evaluation and management of hip pain: an algorithmic approach. J Fam Pract. Aug 2003;52(8):607-17. [Medline][Full Text].

  11. Jacobson T, Allen WC. Surgical correction of the snapping iliopsoas tendon. Am J Sports Med. Sep-Oct 1990;18(5):470-4. [Medline].

  12. Mozes M, Papa MZ, Zweig A, Horoszowski H, Adar R. Iliopsoas injury in soccer players. Br J Sports Med. Sep 1985;19(3):168-70. [Medline].

  13. Lequesne M, Mathieu P, Vuillemin-Bodaghi V, Bard H, Djian P. Gluteal tendinopathy in refractory greater trochanter pain syndrome: diagnostic value of two clinical tests. Arthritis Rheum. Feb 15 2008;59(2):241-6. [Medline].

  14. Kingzett-Taylor A, Tirman PF, Feller J, et al. Tendinosis and tears of gluteus medius and minimus muscles as a cause of hip pain: MR imaging findings. AJR Am J Roentgenol. Oct 1999;173(4):1123-6. [Medline][Full Text].

  15. Brucker PU, Imhoff AB. Functional assessment after acute and chronic complete ruptures of the proximal hamstring tendons. Knee Surg Sports Traumatol Arthrosc. Jul 2005;13(5):411-8. [Medline].

  16. Clanton TO, Coupe KJ. Hamstring strains in athletes: diagnosis and treatment. J Am Acad Orthop Surg. Jul-Aug 1998;6(4):237-48. [Medline].

  17. Bencardino JT, Kassarjian A, Palmer WE. Magnetic resonance imaging of the hip: sports-related injuries. Top Magn Reson Imaging. Apr 2003;4(2):145-60. [Medline].

  18. Akermark C, Johansson C. Tenotomy of the adductor longus tendon in the treatment of chronic groin pain in athletes. Am J Sports Med. Nov-Dec 1992;20(6):640-3. [Medline].

  19. Aksoy B, Oztürk K, Ensenyel CZ, Kara AN. Avulsion of the iliac crest apophysis. Int J Sports Med. Jan 1998;19(1):76-8. [Medline].

  20. Birrell F, Lunt M, Macfarlane GJ, Silman AJ. Defining hip pain for population studies. Ann Rheum Dis. Jan 2005;64(1):95-8. [Medline][Full Text].

  21. Brinks A, van Rijn RM, Bohnen AM, et al. Effect of corticosteroid injection for trochanter pain syndrome: design of a randomised clinical trial in general practice. BMC Musculoskelet Disord. Sep 19 2007;8:95. [Medline][Full Text].

  22. Chung CB, Robertson JE, Cho GJ, et al. Gluteus medius tendon tears and avulsive injuries in elderly women: imaging findings in six patients. AJR Am J Roentgenol. Aug 1999;173(2):351-3. [Medline][Full Text].

  23. Craig RA, Jones DP, Oakley AP, Dunbar JD. Iliotibial band Z-lengthening for refractory trochanteric bursitis (greater trochanteric pain syndrome). ANZ J Surg. Nov 2007;77(11):996-8. [Medline].

  24. Emery CA, Meeuwisse WH, Powell JW. Groin and abdominal strain injuries in the National Hockey League. Clin J Sport Med. Jul 1999;9(3):151-6. [Medline].

  25. Gilmore J. Groin pain in the soccer athlete: fact, fiction, and treatment. Clin Sports Med. Oct 1998;17(4):787-93, vii. [Medline].

  26. Lacroix VJ. A complete approach to groin pain. Phys Sportsmed. 2000;28(1):66-86. [Full Text].

  27. Metzmaker JN, Pappas AM. Avulsion fractures of the pelvis. Am J Sports Med. Sep-Oct 1985;13(5):349-58. [Medline].

  28. Ruane JJ, Rossi TA. When groin pain is more than 'just a strain': navigating a broad differential. Phys Sportsmed. 1998;26(4):2678-103. [Full Text].

  29. Walker P, Kannangara S, Bruce WJ, Michael D, Van der Wall H. Lateral hip pain: does imaging predict response to localized injection?. Clin Orthop Relat Res. Apr 2007;457:144-9. [Medline].

Further Reading

Keywords

trochanteric bursitis, gluteus medius tendonitis/tendinitis, rectus femoris tendonitis/tendinitis, adductor strain/tendonitis/tendinitis, quadriceps tendonitis/tendinitis, hamstring tendonitis/tendinitis, groin injury, groin pull, sports hernia, iliopsoas tendonitis/tendinitis/bursitis, apophysitis, avulsion fracture, tendinopathy

Contributor Information and Disclosures

Author

Jeffrey Rosenberg, MD, Director of Primary Care Sports Medicine Fellowship, Assistant Residency Director, Mountainside Hospital and Mountainside Family Practice Associates; Consulting Staff, New Jersey Sports Medicine Institute
Jeffrey Rosenberg, MD is a member of the following medical societies: American Medical Society for Sports Medicine and Society of Teachers of Family Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

Rutvik Patel, DO, Fellow in Sports Medicine, Mountainside Sports Medicine
Rutvik Patel, DO is a member of the following medical societies: American Academy of Family Physicians and American Medical Society for Sports Medicine
Disclosure: Nothing to disclose.

Medical Editor

Leslie Milne, MD, Assistant Clinical Instructor, Department of Emergency Medicine, Harvard University School of Medicine
Leslie Milne, MD is a member of the following medical societies: American College of Sports Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Russell D White, MD, Professor of Medicine, Department of Community and Family Medicine, University of Missouri-Kansas City School of Medicine, Truman Medical Center Lakewood
Disclosure: Nothing to disclose.

CME Editor

Jon B Whitehurst, MD, Clinical Instructor of Surgery, University of Illinois College of Medicine; Partner and Executive Board Member, Rockford Orthopedic Associates; Orthopedic Chairman, Rockford Memorial Hospital
Jon B Whitehurst, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Society for Sports Medicine, and Arthroscopy Association of North America
Disclosure: Nothing to disclose.

Chief Editor

Sherwin SW Ho, MD, Associate Professor, Department of Surgery, Section of Orthopedic Surgery and Rehabilitation Medicine, University of Chicago
Sherwin SW Ho, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Society for Sports Medicine, and Arthroscopy Association of North America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.